Literature DB >> 30243603

Challenges and controversies in the conservative management of uterine and ovarian cancer.

M Janda1, S McGrath2, A Obermair3.   

Abstract

Uterine cancer is the fifth most common cancer in women worldwide with an estimated 320,000 annual diagnoses. Its most common form, endometrioid adenocarcinoma of the endometrium (endometrial adenocarcinoma [EAC]), is thought to develop through excessive proliferation of endometrial glands, and then increasing steadily in incidence. The current standard treatment for EAC is hysterectomy, which is often curative. However, it may be unacceptably expensive for women with severe medical comorbidities, those who are at risk of intra- and postoperative adverse events and those who desire fertility. Ovarian cancer is the most malignant of all gynaecological cancers, but patients with disease limited to one ovary and patients with non-epithelial tumours may expect a good prognosis. A selected group of young patients who desire fertility may be well treated with conservative surgery. This chapter reviews patient selection, diagnosis, pre-treatment evaluation, treatment options, surveillance and risk of relapse.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Conservative treatment; Ovarian neoplasms; Surgical procedures; Uterine neoplasms; Women's health

Mesh:

Year:  2018        PMID: 30243603     DOI: 10.1016/j.bpobgyn.2018.08.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  4 in total

1.  Fertility-sparing treatment in early endometrial cancer: current state and future strategies.

Authors:  Andreas Obermair; Eva Baxter; Donal J Brennan; Jessica N McAlpine; Jennifer J Muellerer; Frédéric Amant; Mignon D J M van Gent; Robert L Coleman; Shannon N Westin; Melinda S Yates; Camilla Krakstad; Monika Janda
Journal:  Obstet Gynecol Sci       Date:  2020-07-08

Review 2.  Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer.

Authors:  Qian Chen; Zi-Han Zhang; Shu Wang; Jing-He Lang
Journal:  Onco Targets Ther       Date:  2019-12-27       Impact factor: 4.147

Review 3.  The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.

Authors:  Omid Kooshkaki; Afshin Derakhshani; Hossein Safarpour; Souzan Najafi; Parviz Vahedi; Oronzo Brunetti; Mitra Torabi; Parisa Lotfinejad; Angelo Virgilio Paradiso; Vito Racanelli; Nicola Silvestris; Behzad Baradaran
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

4.  Comprehensive bioinformatic analyses of lncRNA-mediated ceRNA network for uterine corpus endometrial carcinoma.

Authors:  Yiran Cai; Jin Cui; Zhisu Wang; Huiqun Wu
Journal:  Transl Cancer Res       Date:  2022-07       Impact factor: 0.496

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.